Ovitrelle powder and solvent 250 micrograms

Ovitrelle contains recombinant hCG.

Ovitrelle is administered to women in order to trigger ovulation during a cycle of artificial insemination, in vitro fertilisation or ICSI.

Its format is OVITRELLE powder and solvent for solution for injection 250 µg (micrograms).

  • ACTIVE SUBSTANCE: choriogonadotropin alfa

Choriogonadotropin alfa is a recombinant human chorionic gonadotropin (hCG recombinant) produced by recombinant DNA technology in Chinese Hamster Ovary cells.

  • QUALITATIVE AND QUANTITATIVE COMPOSITION: 250µg vial choriogonadotropin alfa

Excipients: 27.3 mg mannitol, 0.05 mg poloxamer 188, 0.1 mg L-methionine

  • PHARMACEUTICAL FORM: 2 vial powder+2 vial solvent container
  • CLINICAL PARTICULARS
  • THERAPEUTIC INDICATIONS: Ovitrelle is administered to trigger final follicular maturation and luteinisation after stimulation of follicular growth.
  • CONTRAINDICATIONS
  • POSSIBLE SIDE EFFECTS
  • INTERACTION WITH OTHER MEDICINAL PRODUCTS: No specific interaction studies with Ovitrelle and other medicinal products have been performed however no clinically significant medicinal product interactions have been reported during hCG therapy.
  • Keep out of the reach and sight of children.
  • HOW TO USE OVITRELLE
  • Please note that this a prescription-only item.

Ovitrelle powder and solvent 250 micrograms

Always take Ovitrelle exactly as your doctor has told you.

Source: European Medicines Agency (The European Medicines Agency is a decentralised agency of the European Union, located in London. The Agency is responsible for the scientific evaluation of medicines developed by pharmaceutical companies for use in the European Union).

Cookies allow us to show customized advertising and collect statistical data. By continuing to use our website, you are agreeing to our cookies policy.